Oral simufilam slowed cognitive decline in a randomized withdrawal trial of mild-to-moderate alzheimer's disease

Austin, texas, july 05, 2023 (globe newswire) -- cassava sciences, inc. (nasdaq: sava), a biotechnology company, today announced top-line clinical results from its cognition maintenance study (cms). the cms is a small proof-of-concept study designed to demonstrate the effects of drug versus placebo in a randomized withdrawal trial design. the study enrolled 157 patients with mild-to-moderate alzheimer's disease, a more advanced and difficult-to-treat stage of disease.
SAVA Ratings Summary
SAVA Quant Ranking